Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
Cyto-KIK trial: what clinicians have said so far
CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
- NCT04322955 ↗
- Active, not recruiting
- Mark Stein
- Standard size, estimated: 151–300 verified statements
We haven't built an HCP commentary report on Cyto-KIK (cabozantinib plus nivolumab) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on Cyto-KIK so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 11 posts on X | |
| 3 YouTube videos | |
| 2 podcast episodes |
The trial
ClinicalTrials.gov- Official title
- Cyto-KIK; TRIAL (CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy (Nivolumab) and Targeted Kinase Inhibition (Cabozantinib)
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Kidney Cancer; Renal Cell Carcinoma
- Interventions
- Cabozantinib; Nivolumab; Cytoreductive nephrectomy
- Arms
- Treatment with cabozantinib and nivolumab with nephrectomy · Experimental
- Enrollment
- 38
- Primary outcomes
- Percentage of Participants with a Complete Response
- Sponsor
- Mark Stein with Exelixis, Bristol-Myers Squibb
- Start
- Jun 22, 2020
- Primary completion
- May 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04322955 · updated Jun 5, 2026